PCMC
RNAZ icon

Private Capital Management (Colorado)’s TransCode Therapeutics RNAZ Stock Holding History

Private Capital Management (Colorado)’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-87
Closed -$46.1K – 269
2024
Q3 		$46.1K Buy
87
+68
+358% +$27.5K 0.01% 234
2024
Q2 		$17.6K Buy
+19
New +$16.9K ﹤0.01% 215

Other funds holding RNAZ

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Private Capital Management (Colorado)'s RNAZ Position: Q4 2024 in Review

Private Capital Management (Colorado) sold out of TransCode Therapeutics (RNAZ) in Q4 2024, closing a stake of 87 shares — an estimated $46.1K sold.

Private Capital Management (Colorado) first reported a position in RNAZ in Q2 2024 and held it in 2 quarters. The position peaked at $46.1K in Q3 2024. 3 funds tracked by Wall St. Rank hold RNAZ as of Q4 2024.

  • Private Capital Management (Colorado) reported no remaining TransCode Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Private Capital Management (Colorado) sold 87 TransCode Therapeutics shares in Q4 2024, an estimated $46.1K.
  • Private Capital Management (Colorado) first reported a position in TransCode Therapeutics in Q2 2024 and held it in 2 quarters.
  • Private Capital Management (Colorado)'s TransCode Therapeutics position peaked at $46.1K in Q3 2024.
  • 3 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q4 2024.

Based on Private Capital Management (Colorado)'s 13F filing for Q4 2024, filed 5 Feb 2025.